Biphasic insulin aspart 30 treatment for people with type 2 diabetes: a budget impact analysis based in Thailand
© 2017 Informa UK Limited, trading as Taylor & Francis Group. Objective: To assess the financial consequences of different adoption rate of Biphasic Insulin Aspart (BIAsp) 30 instead of Biphasic Human Insulin (BHI) 30 for people with type 2 diabetes (T2DM) in Thailand from the payer’s perspect...
Saved in:
Main Authors: | Chaicharn Deerochanawong, Natapong Kosachunhanun, Pitthaporn Chotikanokrat, Unchalee Permsuwan |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85041036759&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/58998 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
by: Chaicharn Deerochanawong, et al.
Published: (2019) -
Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: Results from the Indonesian cohort of the A1chieve study
by: Pradana Soewondo, et al.
Published: (2013) -
Basal Insulin Dose Titration for Glycemic Control in Patients With Type 2 Diabetes Mellitus in Thailand: Results of the REWARDS Real-World Study
by: Chaicharn Deerochanawong, et al.
Published: (2020) -
Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
by: Chaicharn Deerochanawong, et al.
Published: (2022) -
Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective
by: Unchalee Permsuwan, et al.
Published: (2018)